ClinicalTrials.gg
Not yet recruitingNCT07850050Updated Oct 30, 2026

SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight

A Phase 3 interventional study of Survodutide and Placebo in Obesity, sponsored by Boehringer Ingelheim. Not yet recruiting at 16 sites in 2 countries. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026First site in United KingdomNewly registered+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Planned enrollment
4th of 22
600 · median 121
Started
2026
with 5 others
Phase 3
9 of 22
3 open now
Registered
19th of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 4th largest by planned enrollment, is one of 6 that started in 2026, is one of 9 in phase 3, and was the 19th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 45 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause. People can join this study if they have a Body Mass Index (BMI) of 30 kg/m² or more, or if their BMI is 27 kg/m² or more and they have one or more weight related health problems. Participants must also have tried to lose weight by dieting at least once in the past without success. People with pre-existing diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps women with overweight or obesity lose weight.

Participants are put into 2 groups randomly, which means by chance. Participants have a 1 in 2 chance of receiving survodutide. One group gets survodutide as an injection under the skin. The other group gets a placebo as an injection under the skin. The placebo looks like the study medicine but does not contain any medicine. Participants take the injections once a week. All participants also receive advice on diet and physical activity.

Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site about 12 times and get a few phone calls from the site staff. At the study visits, doctors regularly check participants' body weight. The results are compared between the 2 groups to see whether the treatment works. The participants fill in questionnaires about their menopause symptoms and how the symptoms affect their daily life. To assess the study endpoints, participants regularly have blood samples taken. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed and dated written in accordance with International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  2. Female (sex assigned at birth) with age >18 years at the time of screening
  3. History of at least one self-reported unsuccessful dietary effort to lose body weight
  4. Women of (WOCBP) must be ready and able to use at least an acceptable effective method of birth control Further inclusion criteria apply.

Exclusion criteria

Exclusion criteria:

  1. Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM)
  2. Glycosylated (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the central laboratory at screening (Visit 1)
  3. Treatment with any medication for the indication of obesity within 90 days before screening
  4. Body weight change (self-reported) >5% within 90 days before screening (Visit 1) Further exclusion criteria apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Survodutide arm

    Combination Product: Survodutide

  • Placebo comparator
    Placebo arm

    Combination Product: Placebo

Interventions

  • Combination productSurvodutide

    Survodutide

    Also known as: BI 456906

  • Combination productPlacebo

    Placebo matching survodutide

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline to Week 52

    Time frame: At baseline and Week 52

Secondary outcomes

  1. Key secondary endpoint: Absolute change in IWQOL-Lite CT total scale score (units on a scale) from baseline to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  2. Absolute change in IWQOL-Lite CT physical scale score (units on a scale) from baseline to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  3. Absolute change in IWQOL-Lite CT physical function scale score (units on a scale) from baseline to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  4. Absolute change in IWQOL-Lite CT psychosocial scale score (units on a scale) from baseline to Week 52

    The Impact of Weight on Quality of Life-Lite Clinical Trial (IWQOL-Lite CT) consists of 20 items, assessing 3 domains of obesity related quality of life: physical, physical function, and psychosocial. Individual composite scale scores and a total score can be computed and are presented on a scale of 0 to 100, with higher scores indicating better function.

    Time frame: At baseline and Week 52

  5. Absolute change in patient-reported outcome 1 from baseline to Week 52

    Time frame: At baseline and Week 52

  6. Absolute change in patient-reported outcome 2 frequency from baseline to Week 52

    Time frame: At baseline and Week 52

  7. Absolute change in patient-reported outcome 2 severity from baseline to Week 52

    Time frame: At baseline and Week 52

  8. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 52

    Time frame: At baseline and Week 52

  9. Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 52

    Time frame: At baseline and Week 52

  10. Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 52

    Time frame: At baseline and Week 52

  11. Absolute change in PROMIS Physical Function score (PF-SF10a) (units on a scale) from baseline to Week 52

    The Patient-Reported Outcomes Measurement Information System (PROMIS) Ability to Participate in Social Roles and Activities SF10a measure assesses perceived ability to perform usual social, family, leisure, and work roles. Items address limitations in engaging in routine activities, and responses are reverse-scored so that higher scores reflect better ability and fewer limitations. The 35-item measure generates a single Ability-to-Participate score.

    Time frame: At baseline and Week 52

  12. Absolute change in Body Mass Index (BMI) (kg/m2) from baseline to Week 52

    Time frame: At baseline and Week 52

  13. Absolute in waist circumference (cm) from baseline to Week 52

    Time frame: At baseline and Week 52

  14. Absolute change in systolic blood pressure (mmHg) from baseline to Week 52

    Time frame: At baseline and Week 52

  15. Absolute change in Glycosylated Haemoglobin A1c (HbA1c) (%) from baseline to Week 52

    Time frame: At baseline and Week 52

  16. Relative change in Low-Density Lipoprotein (LDL) cholesterol (%) from baseline to Week 52

    Time frame: At baseline and Week 52

  17. Relative change in triglycerides (%) from baseline to Week 52

    Time frame: At baseline and Week 52

  18. Relative change in High-Density Lipoprotein (HDL) (%) from baseline to Week 52

    Time frame: At baseline and Week 52

  19. Relative change in non-HDL (%) from baseline to Week 52

    Time frame: At baseline and Week 52

  20. Relative change in high sensitivity C-reactive protein (hsCRP) (%) from baseline to Week 52

    Time frame: At baseline and Week 52

07

Study locations

16 sites
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2028, 20 months later.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 20 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Sep 30, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Jul 26, 2028
CompletionEst.
Jul 26, 2028
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
15 sites added — first site in United Kingdom
Show 15 added (13 United States, 2 United Kingdom)
  • Flourish Research · Birmingham, United States
  • Flourish Research · Northridge, United States
  • Flourish Research · Walnut Creek, United States
  • The Center for Diabetes and Endocrine Care · Fort Lauderdale, United States
  • Jacksonville Center for Clinical Research · Jacksonville, United States
  • Flourish Research · Merritt Island, United States
  • West Orange Endocrinology, PA · Ocoee, United States
  • Flourish Research · Mandeville, United States
  • Flourish Research · Metairie, United States
  • Flourish Research · Bowie, United States
  • Lucas Research, Inc. · Morehead City, United States
  • McKay-Dee Hospital · Ogden, United States
  • Diabetes Associates Medical Group · Orange, United States
  • Glasgow Royal Infirmary · Glasgow, United Kingdom
  • Leicester General Hospital · Leicester, United Kingdom
across 2 updates, Oct 14, 2026 – Oct 30, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 3 updates
  1. Oct 30, 2026
    3 sites added — first site in United Kingdom
    Show 3 added (2 United Kingdom, 1 United States)
    • Diabetes Associates Medical Group · Orange, United States
    • Glasgow Royal Infirmary · Glasgow, United Kingdom
    • Leicester General Hospital · Leicester, United Kingdom
  2. Oct 14, 2026
    12 sites added
    Show 12 added (12 United States)
    • Flourish Research · Birmingham, United States
    • Flourish Research · Northridge, United States
    • Flourish Research · Walnut Creek, United States
    • The Center for Diabetes and Endocrine Care · Fort Lauderdale, United States
    • Jacksonville Center for Clinical Research · Jacksonville, United States
    • Flourish Research · Merritt Island, United States
    • West Orange Endocrinology, PA · Ocoee, United States
    • Flourish Research · Mandeville, United States
    • Flourish Research · Metairie, United States
    • Flourish Research · Bowie, United States
    • Lucas Research, Inc. · Morehead City, United States
    • McKay-Dee Hospital · Ogden, United States
    + 1 other change: verification date
  3. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850050
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Jul 26, 2028 (estimated)
Completion
Jul 26, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion